ATE188257T1 - Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren - Google Patents

Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren

Info

Publication number
ATE188257T1
ATE188257T1 AT96913202T AT96913202T ATE188257T1 AT E188257 T1 ATE188257 T1 AT E188257T1 AT 96913202 T AT96913202 T AT 96913202T AT 96913202 T AT96913202 T AT 96913202T AT E188257 T1 ATE188257 T1 AT E188257T1
Authority
AT
Austria
Prior art keywords
diagnostic
therapeutic procedures
reagents derived
genetic therapeutic
metastasis suppression
Prior art date
Application number
AT96913202T
Other languages
English (en)
Inventor
Jin-Tang Dong
J Carl Barrett
Patricia W Lamb
John T Isaacs
Original Assignee
Univ Johns Hopkins
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Us Health filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE188257T1 publication Critical patent/ATE188257T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT96913202T 1995-04-28 1996-04-25 Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren ATE188257T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/430,225 US6204000B1 (en) 1995-04-28 1995-04-28 Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
PCT/US1996/005848 WO1996034117A1 (en) 1995-04-28 1996-04-25 Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene kai1

Publications (1)

Publication Number Publication Date
ATE188257T1 true ATE188257T1 (de) 2000-01-15

Family

ID=23706611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913202T ATE188257T1 (de) 1995-04-28 1996-04-25 Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren

Country Status (8)

Country Link
US (3) US6204000B1 (de)
EP (1) EP0822993B1 (de)
JP (1) JP4201057B2 (de)
AT (1) ATE188257T1 (de)
AU (1) AU720500B2 (de)
CA (1) CA2219221A1 (de)
DE (1) DE69605908D1 (de)
WO (1) WO1996034117A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204000B1 (en) * 1995-04-28 2001-03-20 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
US5863735A (en) * 1997-02-24 1999-01-26 Incyte Pharmaceuticals, Inc. Human transmembrane 4 superfamily protein
US6824995B1 (en) 1998-03-03 2004-11-30 Emory University Diagnostic for metastatic prostate cancer
AU2985199A (en) * 1998-03-03 1999-09-20 Emory University Diagnostic for metastatic prostate cancer
US20020115837A1 (en) * 2000-01-28 2002-08-22 Turner C. Alexander Novel human membrane proteins and polynucleotides encoding the same
AUPR783601A0 (en) * 2001-09-20 2001-10-18 University Of Melbourne, The Prognostic method
PL1720972T3 (pl) 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
CA2832452C (en) * 2006-03-21 2014-11-18 Akzo Nobel N.V. Additive for preserving the fluidity of fluids containing gas hydrates
FI2343362T4 (fi) 2006-07-14 2024-07-04 Patheon Holdings I B V Parannettu menetelmä solujen viljelyä varten
WO2010096720A2 (en) * 2009-02-19 2010-08-26 Cornell University Methods and compositions for altering photophysical properties of fluorophores via proximal quenching
GB0916124D0 (en) 2009-09-15 2009-10-28 Univ Cardiff Method and kit for the classification and prognosis of wounds
GB201021182D0 (en) 2010-12-14 2011-01-26 Univ Cardiff Methdo and kit for the classification and prognosis of chronic wounds
GB201103898D0 (en) 2011-03-08 2011-04-20 Univ Cardiff Molecular targets for healing or treating wounds
EP2708234B1 (de) * 2012-09-12 2016-05-25 King Faisal Specialist Hospital And Research Centre Tetraspanin CD82 als Diagnose- und/oder Therapiemodul zur Erkennung und/oder Abweisung eines Xenotransplantats
KR101723292B1 (ko) * 2015-05-06 2017-04-04 서울대학교산학협력단 Kai1 폴리펩타이드 또는 이를 코딩하는 유전자를 포함하는 혈관신생 억제용 조성물 및 이의 용도
KR101757530B1 (ko) * 2015-05-06 2017-07-13 서울대학교산학협력단 조혈모세포의 세포주기를 조절하는 kai1 단백질 및 이의 용도
EP3541939A4 (de) 2016-11-17 2020-06-24 Ramot at Tel-Aviv University Ltd. Modulatoren des humanen kai1-metastasesuppressorgens verfahren und verwendungen davon
WO2020154034A1 (en) * 2019-01-25 2020-07-30 Children's Medical Center Corporation Compositions and methods for treating muscular dystrophy and related disorders
US20240382559A1 (en) * 2021-08-31 2024-11-21 Pusan National University Industry-University Cooperation Foundation Pharmaceutical composition comprising kai1 polypeptide for inhibition of hepatic fibrosis and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204000B1 (en) * 1995-04-28 2001-03-20 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1

Also Published As

Publication number Publication date
JP4201057B2 (ja) 2008-12-24
JPH11504803A (ja) 1999-05-11
US6204000B1 (en) 2001-03-20
CA2219221A1 (en) 1996-10-31
US20050250102A1 (en) 2005-11-10
WO1996034117A1 (en) 1996-10-31
US20020058257A1 (en) 2002-05-16
AU720500B2 (en) 2000-06-01
AU5579096A (en) 1996-11-18
EP0822993A1 (de) 1998-02-11
EP0822993B1 (de) 1999-12-29
DE69605908D1 (de) 2000-02-03
US6756201B2 (en) 2004-06-29

Similar Documents

Publication Publication Date Title
DE69605908D1 (de) Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren
KR960700752A (ko) 광범위한 종양억제 유전자와 유전자 생성물 그리고 종양억제 유전자 요법의 방법
DE69735939D1 (de) Fhit proteine und nukleinsäuren sowie darauf basierende verfahren
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
WO1996034953A3 (en) Cd16-ii variants
EP0961833A4 (de) Hyaluronidase aus menschlichem plasma
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
DE69332642D1 (de) Methoden zur detektion von mikrometastasen bei prostata-krebs
DE69739478D1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
AU3368497A (en) Human dnase i hyperactive variants
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
CY1105240T1 (el) 5’ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
ATE226094T1 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
EP1546714A4 (de) Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen
WO2000008157A3 (en) Human anion transporter genes atnov
ATE207536T1 (de) Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties